Cargando…

Correction Notice: Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061680/ https://www.ncbi.nlm.nih.gov/pubmed/33898933 http://dx.doi.org/10.1097/HS9.0000000000000577

Ejemplares similares

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
por: Sousos, Nikolaos, et al.
Publicado: (2020)

Chronic Lymphocytic Leukemia and Myelofibrosis
por: Darawshy, Fares, et al.
Publicado: (2018)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Correction: JAK inhibitors and COVID-19
Publicado: (2023)

Correction: Chronic lymphocytic leukemia treatment algorithm 2022
por: Hampel, Paul J., et al.
Publicado: (2022)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
por: Angotzi, Francesco, et al.
Publicado: (2022)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Notice of Correction
Publicado: (2019)

Correction notice
por: Samardžija, M., et al.
Publicado: (2021)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

A notice of correction
Publicado: (2012)

Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
por: Roessner, Philipp M., et al.
Publicado: (2021)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2019)

Correction Notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction notice
Publicado: (2022)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Correction to: Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
Publicado: (2023)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
por: Lichtman, Marshall A.
Publicado: (2022)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Correction: Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs
por: Shen, Min, et al.
Publicado: (2013)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022)

Correction: potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis
por: Mukherjee, Priyabrata, et al.
Publicado: (2013)

Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
por: Morscio, Julie, et al.
Publicado: (2018)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era
por: Del Sordo, Rachele, et al.
Publicado: (2017)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
por: Calissano, Carlo, et al.
Publicado: (2022)

Correction: ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution
por: Royo, Romina, et al.
Publicado: (2022)

New emerging therapies in the management of chronic lymphocytic leukemia
por: Li, Xiao-Lin, et al.
Publicado: (2016)

Correction: Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n2pdqamo9chdq6aa0gbrgdthov